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Abstract 
Objectives 
To compare the long term results of uterine artery embolisation (UAE) with surgery 
for women with symptomatic uterine fibroids using the REST trial cohort.  
Design 
A pragmatic, open, multicentre, randomised controlled trial. 
Setting 
Secondary care.  27 participating UK centres.  
Participants 
157 women aged 18 and over were randomised (in a 2:1 ratio): 106 to UAE and 51 to 
surgery (hysterectomy 42, myomectomy 9). Those who had symptomatic fibroid(s) 
larger than 2 cm were candidates for randomisation. Exclusion criteria included 
subserosal pedunculated fibroids, recent or ongoing pelvic infection, pregnancy, 
severe allergy to iodinated contrast media and any contraindication to surgery.  
Interventions 
Surgical arm included either hysterectomy or myomectomy compared with the UAE 
arm which was a bilateral uterine artery embolisation.  
Main outcome measures 
Quality of life at 5 years as assessed by the Medical Outcomes Study 36-item Short 
Form General Health Survey (SF-36). Secondary measures included complications, 
adverse events and the need for further intervention.  A cost utility analysis was also 
performed. 
Results 
There were no significant differences between groups in any of the eight components 
of the SF-36 scores at 5 years (minimum p = 0.45). For 6 of the 8 components of the 
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SF-36 the 95% confidence intervals exclude a mean difference in excess of 10 points. 
Symptom score reduction and patient satisfaction with either treatment was very high 
with no group difference. Major adverse events rates were similar in both groups 
(19% embolization and 25% surgery, p=0.40). The intervention rate for treatment 
failure or complications in the UAE arm increased from 13% at 12 months to 32% at 
5 years. In contrast the intervention rate in the surgical arm remained at 4%. Initial 
cost benefit of UAE over surgery at 12 months was lost due to subsequent 
interventions, with treatments being cost neutral at 5 years.  
Conclusions 
UAE is a satisfactory alternative to surgery for women with fibroids. The less 
invasive nature of UAE, needs to be balanced against the need for re-intervention in a 
significant minority. The choice should lie with the informed patient.  
Trial registration: ISRCTN.org number, ISRCTN23023665. 
Funding:  Chief Scientist Office (CSO), Edinburgh, Scotland 
 
What is already known on the subject ? 
•Uterine artery embolisation is an accepted alternative to surgery for women with 
fibroids. 
•Advantages include a more rapid convalescent period and uterine preservation 
•A significant minority require further invasive treatment in the first year for either 
complications or recurrent and persistent symptoms.  
What this study adds ? 
•The majority of further interventions following UAE (surgery or repeat UAE) occur 
beyond the first year of follow up. 
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•Further research on UAE should focus on better patient selection and outcomes.The 
apparent economic advantage of UAE at 2 years is lost at 5 years that has important 
implications for the health service. 
Introduction 
Uterine fibroids are a common health problem in pre-menopausal women and 
treatment is traditionally surgical (hysterectomy or myomectomy). Since its inception 
in 19951 uterine artery embolization (UAE) has become a well established alternative 
treatment for those wishing to avoid surgery and preserve their uterus. The American 
College of Obstetrics and Gynaecology, the Royal College of Obstetricians and 
Gynaecologists (U.K.) and the National Institute for Health and Clinical Excellence 
(NICE) (U.K.) have all endorsed its safety and short term efficacy with the caveat that 
longer term outcomes are required. 
The randomised trials comparing UAE with surgery have all reported short term 
outcomes2,3,4,5 but long term clinical data have only recently been published.6  The 
clinical findings show some similarity with our data but this paper does not include an 
economic analysis 
The aim of this study is to provide 5 year clinical and economic outcomes of the 
REST trial (uterine-artery embolization versus surgery for symptomatic uterine 
fibroids) cohort and to determine whether the previously published early results are 
durable.4 This will allow a more effective comparison of UAE with surgery and 
provide vital information to doctors, patients and health care providers.  
 
Methodology 
Trial Design 
Formatted: Highlight
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The REST trial commenced in November 2000 in seven Scottish hospitals but later 
expanded to include a total of 27 centres, including two in England. 
Ethics committee approval was granted by the Multicentre Research Ethics 
Committee and local approval granted at every centre. A trial coordinator was 
appointed to supervise the trial and 4 research nurses covered the 27 sites together 
with a research fellow in gynaecology.  
A randomised parallel group study was carried out. Patients were randomised 
according to a computer generated (permuted blocks) schedule held by the study 
coordinator. Randomisation used a 2:1 ratio with twice as many subjects being 
allocated to the new treatment (UAE). Randomisation was stratified by centre and 
was done centrally by the trial coordinator once the entry criteria had been confirmed 
and baseline data submitted. The trial randomised 157 women with symptomatic 
fibroids to either UAE 106, or surgery 51 (hysterectomy 42, myomectomy 9). 
The 12 month results were completed in September 2005 and have been published.4 
The patients were followed annually for a further 4 years, collecting all the original 
outcome measures, which was funded as a separate grant from the CSO.  
 
Participants 
Patients were recruited at the local gynaecology clinics. Women at least 18 years old 
were eligible if they had one or more fibroids of more than 2cm in diameter that could 
be adequately imaged using magnetic resonance imaging (MRI) and causing  
symptoms (such as menorrhagia or bulk symptoms) and were considered by their 
gynaecologist to justify surgical treatment. Exclusion criteria included a 
contraindication to MRI, severe allergy to iodinated contrast media, subserosal 
pedunculated fibroids, recent or ongoing pelvic inflammatory disease and any 
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contraindication to surgery. There was no upper limit on the size or number of 
fibroids.  
Data were collected by a research coordinator using a combination of postal 
questionnaires and telephone contact. Outcomes were recorded annually after the first 
12 months up to 5 years following treatment. 
 
Interventions 
Experienced interventional radiologists carried out the embolisation procedure with 
referral to specialist centres from peripheral units where required. Hysterectomy and 
myomectomy were carried out at each local centre. The method of hysterectomy and 
myomectomy was left to the discretion of the operator and was not prescribed. 
Similarly the precise technique for embolisation was left to the operator but both 
uterine arteries had to be embolised and the particle size of the embolic agent 
standardised at 500-710 microns. 
 
Outcome measures 
The primary outcome measure was quality of life (QoL) as assessed at 1 year on the 
Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) with 
scores ranging from 0 to 100, higher scores indicating better health-related QoL. The 
primary outcome measure and all the secondary outcomes were re-evaluated at 5 
years (forming the content of this report). Secondary outcomes included the EuroQol-
5D questionnaire, an 11-point symptom score, ranging from -5 (markedly worse) to 
+5 (markedly better), a satisfaction score (measuring whether patients would 
recommend the procedure to a friend), complications, adverse events and the need for 
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further intervention for treatment failure. Follow up intervals were 1, 6, 12, months 
and annually thereafter.  
 
Complications and Serious Adverse Events  
All complications were graded using the Society of Interventional Radiology (SIR) 
classification as shown below.7  
Categories 1-2 were subsequently grouped as minor and 3-5 as major complications. 
Three of the investigators (two gynaecologists and a radiologist) independently 
categorised the grades of complications.  In cases of non-agreement the worse grade 
was used. Most discrepancies were of one category. 
 
Society of Interventional Radiology Complication Grading:  
1    No therapy, no consequence 
2 Nominal therapy, no consequence, includes overnight admission for 
observation only 
3 Requires therapy, minor hospitalisation ( <48 hours) 
4 Requires major therapy, unplanned increase in level of care, prolonged 
hospitalisation ( >48 hours) 
5 Permanent adverse sequelae 
If a complication included death, life threatening events, initial or prolonged 
hospitalisation, disability, congenital anomaly or intervention required to prevent 
permanent impairment or damage, then it was logged as an adverse event. All 
category 3-5 complications were recorded as adverse events.8   
 
Further Intervention for Persistent or Recurrent Symptoms  
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Further interventions required for persistent or recurrent symptoms are different for 
each arm of the trial. In the UAE arm, it included repeat UAE and therapeutic surgery 
(e.g. hysterectomy, myomectomy and endometrial ablation). In the surgical arm, it 
could include removal of cervical stump (following subtotal hysterectomy), repeat 
myomectomy and endometrial ablation (following myomectomy).  
 
 
Ovarian Failure  
This was defined by a level of follicular stimulating hormone (FSH) > 40 IU/L and 
was assessed pre-treatment and up to one year after both UAE and surgery. These 
results have been published elsewhere.9  In women of the age of those in this study, 
further follow up with hormone assessment was unlikely to provide additional useful 
information. 
 
Sample Size 
The original power calculation required a total study size of 200 participants to give 
90% power to detect at the 5% significance level a difference of 10 points in the 
SF-36 score at 12 months (the primary endpoint). This calculation took account of the 
baseline adjustment and the unbalanced randomisation. It was subsequently agreed to 
reduce the power to 80%, which required a total sample size of 150 participants.  This 
decision was taken in consultation with the main trial funder, in view of the slow 
initial recruitment rate. 
An independent data monitoring committee reviewed the accumulating results and 
any SAEs on an on-going basis. They followed the highly conservative ‘Peto’ 
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approach to guide any recommendation to terminate the trial prematurely. Stopping 
rules did not need to be implemented. 
 
 
Statistical methods 
Analysis was by intention to treat. The quality of life scales (SF-36 and EuroQol) 
were analysed using analysis of covariance to adjust for baseline values. Other 
comparisons between groups used a two sided Student’s t-test for continuous data and 
Fisher’s Exact test for categorical data. A Kaplan-Meier survival curve was used to 
look at the time from initial treatment to further intervention for treatment failure and 
complications. 
 
Economic  analysis 
Data on total resource use were collected prospectively up to five years post 
randomisation. This included total length of initial hospital stay, outpatient visits, 
visits to general practitioners and other hospital visits associated with further 
intervention (UAE, hysterectomy, hysteroscopic-assisted removal of expelled fibroid, 
other gynaecological procedures and associated complications). Unit costs for all 
resources used were obtained from routinely collected data and published literature.  
These were applied to the resource use to determine the direct healthcare costs 
associated with each patient from the perspective of the NHS. All costs were 
calculated at 2008 values (UK £). Patient-specific quality adjusted life years (QALYs) 
were estimated from patient responses to the EuroQol-5D questionnaire using a 
standard weighting process.10 The mean costs and QALYs gained were calculated for 
the overall five-year period. All costs and QALYs were discounted at 3.5% as 
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recommended by NICE.11 The 95% confidence intervals for the difference in mean 
costs and QALYs were estimated using bias-corrected and accelerated bootstrap 
methods. In addition, sensitivity analysis was also carried out on key unit costs by 
varying one component at a time. 
 
 
 
 
 
Results        
The original trial randomised 157 women to UAE (106) and surgery (51) between 
2000 - 2004. The groups were well matched at baseline (Table 1). 
Table 1.  Baseline comparison of the two treatment groups 
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Variable N Mean
Age (years) 104 43.6
Largest fibroid diameter (cm)1 100 7.5
Uterine volume (mls) 98 579
SF-362
physical function 104 82
role- physical 104 51
bodily pain 104 52
general health 104 61
vitality 103 41
social function 104 63
role- emotional 104 60
mental health 103 63
EuroQol 103 70
Main symptom:
  Bleeding 56 55%
  Pain 19 19%
  Pressure 23 23%
  Other 4 4%
Total 102
Table 1    Baseline comparison of the two treatment groups
Embolisation Surgery
StDev N Mean StDev
5.5 50 43.3 7.1
3 48 8.5 3.9
447 48 701 627
19 50 77 20
41 50 45 42
22 50 50 22
19 50 60 23
22 50 42 23
27 50 58 30
43 50 57 43
18 50 63 22
16 50 63 20
29 58%
7 14%
12 24%
2 4%
50
 
113/148 patients (9%) had largest fibroid of less than 4cm diameter and 2/148 patients (1%) had largest 
fibroid of less than 3cm diameter. 
2SF-36 and EuroQol range from 0 (worst possible) to 100 (best possible). 
 
Eight patients (5%) did not receive their allocated treatment (five did not receive UAE 
and three did not receive surgery). There was one technical failure in the surgical arm 
with a myomectomy being converted to hysterectomy due to technical difficulties. 
Three patients in the UAE arm had a failed procedure due to difficulty identifying or 
catheterising one or both uterine arteries. Two subsequently underwent a 
hysterectomy and one had no further treatment. All the hysterectomies and 
myomectomies were performed through an abdominal incision. 
Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in 
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The five year follow up study was completed in 2009. Only 10 (10%) (UAE group) 
and 3 (6%) (surgery group) were lost to 5 year follow up (Figure1).  
  
Figure 1. CONSORT diagram showing the enrolment and follow-up for the REST 
trial. 
 
 
 
 
Primary Outcome 
The primary outcome measure (the SF-36 health-related QoL score) was available for 
138 of the 157 women (88%) at 5 years. The results of the SF-36 and Euroqol-5D at 
3, 4 and 5 years are shown in Table 2. There were no significant differences between 
groups in any of the components of the QoL measures.  For 6 of the 8 components of 
the SF-36 the 95% confidence intervals exclude a mean difference in excess of 10 
389 Excluded 
 74 Did not meet inclusion        
criteria 
192 Declined participation 
123 had other reasons 
 
 
157 Underwent randomisation 
 
106 Assigned to UAE group 
101 Underwent UAE 
(including 3 technical failures) 
5 did not undergo UAE 
 
 
 
51 Assigned to surgical group 
48 Underwent surgery 
 3 Did not undergo surgery 
 1 Underwent UAE 
 2 Were not treated 
 
 
 1 year – 95 included in analysis  
  11 lost to follow-up 
3 years – 80 included in analysis  
              26 lost to follow-up 
 
4 years – 77 included in analysis 
 29 lost to follow-up 
 
5 year –  96 included in analysis 
 10 lost to follow-up 
 
1 year – 45 included in analysis 
   6 lost to follow-up 
 
3 years – 41 included in analysis 
 10 lost to follow-up 
 
4 years – 36 included in analysis 
 15 lost to follow-up 
 
5 years – 48 included in analysis   
  3  lost to follow-up 
 
546 Patients screened 
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points. Both treatment arms showed a gain in QoL to reach levels comparable with 
age matched normative QoL SF-36 data (Figure 2).  
 
 
 
 
Figure 2 shows the mean score for each of the eight domains of the SF-36. There are 
no differences between the two arms which both closely match the normative data for 
healthy women of this age group in the UK. Scores for the SF-36 range from 0 (worst 
possible) to 100 (best possible). 
Secondary Outcomes 
At 5 years the mean symptom score (-5 markedly worse to +5 markedly better) was 
+4.5 in the UAE group and +4.8 in the surgical group (p=0.08). The percentage of 
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women who reported that they would recommend their treatment to a friend, was high 
in both treatment groups (90% in the UAE group and 87% in the surgical group, 
p=0.56). (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Effects of uterine-artery embolization and surgery on measures of quality of 
life (SF-36, EuroQoL), symptom score and patient satisfaction at 3, 4 and 5 years. 
      Difference between groups (S - E) 
 UAE (E) Surgery (S)  accounting for pre-procedure levels 2 
 Mean SD Mean SD  Difference 95%CI p 
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      Difference between groups (S - E) 
 UAE (E) Surgery (S)  accounting for pre-procedure levels 2 
 Mean SD Mean SD  Difference 95%CI p 
3 Year SF-36 1 N=79  N=40       
physical function 91 16 89 22  1 -4 to 7 0.64 
role- physical 86 31 84 33  0 -12 to 12 0.99 
bodily pain 78 23 81 27  4 -5 to 13 0.39 
general health 80 18 79 23  0 -7 to 7 0.97 
vitality 69 20 66 21  -3 -10 to 5 0.49 
social function 90 18 87 26  -2 -9 to 6 0.65 
role- emotional 86 31 88 30  2 -9 to 14 0.68 
mental health 79 16 78 19  0 -6 to 6 0.99 
          
4 Year SF-36 1 N=70  N=36       
physical function 92 15 93 15  3 -3 to 8 0.34 
role- physical 89 27 92 25  2 -8 to 13 0.67 
bodily pain 80 21 82 22  3 -5 to 11 0.45 
general health 80 17 78 23  -1 -8 to 6 0.72 
vitality 66 20 66 22  -3 -10 to 5 0.49 
social function 88 18 89 23  1 -6 to 9 0.69 
role- emotional 86 28 88 28  1 -10 to 12 0.90 
mental health 78 18 78 18  0 -7 to 6 0.90 
          
5 Year SF-36 1 N=94  N=44       
physical function 90 18 87 24  0 -7 to 6 0.96 
role- physical 84 32 81 36  -2 -14 to 10 0.71 
bodily pain 79 22 81 27  2 -6 to 10 0.59 
general health 78 19 76 24  -1 -8 to 6 0.76 
vitality 63 22 63 25  -1 -9 to 7 0.84 
social function 86 23 85 29  1 -7 to 10 0.81 
role- emotional 82 35 85 34  4 -9 to 16 0.57 
mental health 76 17 74 24  -2 -9 to 4 0.45 
          
          
EuroQoL 3          
3 Year 87 11 84 17  -1 -6 to 4 0.56 
4 Year 87 11 83 16  -2 -7 to 3 0.39 
5 Year 85 13 80 20  -3 -9 to 3 0.29 
          
 
 
 
Table 2 continued. 
 
 UAE Surgery  
 Mean SD Mean SD  
Absolute 
difference 95% CI p 
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Symptom score 4  
3 years 4.3 0.2 4.7 0.1  -0.4 -0.8 to 0.0 0.04 
4 years 4.4 0.2 4.6 0.2  -0.2 -0.7 to 0.3 0.42 
5 year 4.5 0.1 4.8 0.1  -0.3 -0.6 to 0.0 0.08 
          
          
Recommend to 
friend 5 yes  yes   (S - E)    
3 years 58/68 85% 30/35 86%  0% -14% to 15% 0.95 
4 years 58/63 92% 22/27 81%  -11% -27% to 6% 0.20 
5 year 84/93 90% 40/46 87%  -3% -15% to 8% 0.56 
          
 
1 Scores for the SF-36 range from 0 (worst possible) to 100 (best possible) 
 
2 For the differences in quality-of-life scores (on the SF-36 and EuroQol) between the surgical group and the UAE group, the 
analysis of covariance is adjusted for baseline values, so the differences between the groups are not simple numerical differences. 
Negative values indicate higher scores in the UAE group, and positive numbers indicate higher scores in the surgical group. 
 
3 Scores on the Euroqol range from 0 (worst possible) to 100 (best possible) 
 
4 Symptom score (-5 (markedly worse) to +5 (markedly better) 
 
5 Patient satisfaction – recommend to a friend, yes/no 
 
 
Minor Complications 
A total of 82 minor complications were reported over the 5 year period (20 surgical, 
62 UAE). Minor complications were reported more frequently in the first year (in the 
surgical group 10 (20%) women reported 16 complications while in the UAE group 
36 (34%) women reported 50 complications).4 There were few minor complications 
reported in the 1-5 year period. In the surgical treatment group 4 (8%) women 
reported 4 complications (1 vaginal discharge; 2 urinary symptoms; 1 
proteinuria/pyrexia) compared with 12 (13%) reporting 12 complications in the UAE 
arm (4 vaginal discharge; 2 abdominal pain; 2 urinary symptoms; 4 other).   
 
 
 
Major Adverse Events and Complications 
A total of 33 major adverse events and major complications were reported over the 5 
year period (13 (25%) surgical, 20 (19%) UAE) and rates were similar in both groups 
Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in 
patients with symptomatic uterine fibroids (REST trial): 5 year results. 
 
19 
(p=0.40). Most of these occurred in the first year with 10 (20%) women in the 
surgical group and 13 (12%) in the UAE group. Between one to five years 3 (6%) in 
the surgical group reported a major complication and 7 (7%) in the UAE arm). (Table 
3). 
Table 3. Major adverse events, complications and further interventions. 
 Surgery Embolisation 
   
Major adverse events and complications  
Up to 1 year 10 13 
 1 Wound exploration under general 
anaesthetic 
1 Severe vasovagal event  
 2 Operative haemorrhage  2 Pain and infection requiring re-admission  
 2 Anaesthetic complications  3 Pain and fibroid expulsion at 3, 4 and 6 
weeks  
 3 Wound infection  1 Haematometria (6 months untreated) then 
hysteroscopic endometrial ablation at 15 
months 
 1 Wound haematoma  1 Severe persistent pain requiring 
hysterectomy  
 1 Urinary retention  1 Pelvic abscess requiring hysterectomy  
  2 Temporary amenorrhea  
  2 Breast cancer  
   
1 – 5 years1 3 7 
 1 Death – motor neurone disease  1 Death – adrenal cancer  
 1 Anal sphincter repair  1 Blood transfusion 
 1 Urinary tract infections  2 Severe persistent pain, 1 requiring 
hysterectomy  
  1 Severe persistent pain and fibroid 
expulsion at 13 months  
  1 Laparoscopy and hysteroscopy 
  1 D & C  
   
Further intervention for persistent or recurrent symptoms  
Up to 1 year 1 12 
 1 Operative complication (myomectomy  
to hysterectomy)  
3 Technical failure of procedure  
  4 Repeat embolization  
  5 Hysterectomy2  
   
1-5 years  17 
  4 Repeat embolization  
  13 Hysterectomy  
   
 
1 After 1 year all deaths and only adverse events considered to be related to treatment are included in the table.  In the 
embolization group there was also 1 cholecystectomy, 1 femoral hernia repair, 1 bowel polyp excision, 1 bowel resection for 
Crohn’s disease.  In the surgery group there was also 1 cholecystectomy. 
 
2  Includes 1 woman who also had a repeat embolization and 2 who were not embolized after randomization but subsequently had 
surgery (1 myomectomy , 1 hysterectomy) 
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Further Intervention for Persistent or Recurrent Symptoms 
Eleven patients (10%) in the UAE group and one (2%) in the surgical group had a 
further intervention for further symptoms during the first 12 months of the study, the 
details of which have been previously reported.4 At 5 years a further 17 (16%) 
patients in the UAE group had either a repeat UAE (4) or a hysterectomy (13). There 
were no further interventions in the surgical arm beyond 1 year. (Figure 3). 
 
The Cumulative Risk for Further Intervention 
The cumulative risk for further intervention includes both those for recurrent 
symptoms and complications/SAEs and is probably more useful information for 
individual patients to understand. The cumulative risk for further intervention over the 
entire 5 year period is 32% after UAE and 4% after surgery. (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Kaplan-Meier curve showing freedom from further intervention for either 
treatment failure or complications. 
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Pregnancies 
Twelve pregnancies occurred in five women (2 in the myomectomy group and 10 in 
the UAE group). All pregnancies were planned. In the myomectomy group one 
patient had two elective Caesarean sections, resulting in successful live births. No 
peri-operative complications occurred.  
In the UAE group, 4 of the 10 (40%) pregnancies resulted in miscarriage and 1 
resulted in an ectopic pregnancy requiring laparoscopic salpingectomy. Four 
pregnancies resulted in successful live births (34, 35, 38 and 41 weeks gestation). 
Three  were delivered by Caesarean section with one post-partum haemorrhage due to 
an atonic uterus and another due to a morbidly adherent placenta. In a further case, the 
placenta was described as morbidly adherent but delivery was not associated with 
excessive blood loss. One intrauterine death of the foetus occurred at 33 weeks. The 
birth weight of the fetus was above the 90th centile with no evidence of intrauterine 
543210
100
95
90
85
80
75
70
65
Years
Pe
rc
en
ta
ge
 w
it
ho
ut
 fu
rt
he
r 
in
te
rv
en
ti
on
Embolisation
Surgery
Randomised to:
Freedom from further intervention for treatment failure or complication
Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in 
patients with symptomatic uterine fibroids (REST trial): 5 year results. 
 
22 
growth retardation (making placental insufficiency unlikely). No abnormality was 
found at post-mortem examination.  
 
Ovarian Function after Treatment   
Ovarian function after treatment was assessed by measuring gonadotrophin levels and 
ovarian failure was defined as an FSH in excess of 40IU/l. There were no cases of 
premature ovarian failure (i.e. ovarian failure in women under 40 years of age). 
Ovarian failure developed in a total of 16 patients (13 UAE and 3 surgery (2 
myomectomy, 1 hysterectomy)) of whom 14 were aged > 45 years. Both younger 
patients (43 and 44 years; received UAE) and 4 of the patients aged > 45 years (all 
underwent UAE) had an elevated basal FSH at the time of treatment (>19 IU/l) 
suggesting their peri-menopausal status prior to treatment.  
In regard to their bleeding pattern, follow-up review indicated that all 15 patients who 
experienced ovarian failure (16th patient underwent hysterectomy) had some vaginal 
bleeding in the year following treatment. Two women ceased to bleed within 6 
months and eight patients had their final bleed within 12 months of UAE.  In the 
course of the 5 year follow-up 26 in the UAE group ceased bleeding. 
 
Economic Evaluation 
During the year 1 to year 5 follow up, the UAE arm of this study was associated with 
a greater number of further interventions, and subsequent greater resource use and 
costs compared with the surgery arm (mean costs of £671 compared with £318). This 
finding is in contrast to that observed in the first 12 months when UAE was associated 
with substantially lower costs compared with surgery (mean costs of £1727 compared 
with £2673).4 As a result, over the period from baseline to five year follow up, UAE 
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no longer has a cost benefit compared with surgery; the total cost associated with 
UAE was similar to that of surgery (difference of £554). Similarly, there was little 
difference in QALYs between the UAE group and surgery group for the five year 
period (difference of -0.02 QALYs). Sensitivity analyses for year one to year five did 
not alter the results when assumptions were varied around the cost of MRI and US. 
Increasing the cost of agent and reducing the cost of inpatient stay showed a slightly 
higher, now significant, mean difference between the two treatments. (Table 3). 
 
Table 3. Economic analysis  
 UAE Surgery Difference 
Mean cost (£) per patient (Year 1 to 5) (95% CI) 
Basecase  671 (432 to 910) 318 (77 to 559) -305 (-633 to 30) 
Sensitivity analysis 
Cost of MRI & US doubled 689 (445 to 934) 319 (78 to 560) -309 (-612 to 19) 
Cost of MRI & US doubled + agent cost 709 (460 to 958) 319 (78 to 560) -352 (-690 to -4) 
Cost of IP stay reduced by 50% 601 (383 to 819) 207 (57 to 357) -352 (-613 to -94) 
Cost of IP stay reduced by 65% 580 (366 to 794) 174 (45 to 303) -359 (-615 to -139) 
    
Mean cost (£) and Quality Adjusted Life Years per patient (Year 0 to 5) 
Cost 2467 (2076 to 2857) 2961 (2509 to 3413) 554 (-43 to 1173) 
Quality Adjusted Life Years 1.57 (1.52 to 1.62) 1.60 (1.55 to 1.66) -0.02(-0.05 to 0.05) 
    
MRI - magnetic resonance imaging; US - ultrasonography; IP - inpatient.  Calculations were based on the following unit cost estimates: uterine-artery 
embolisation £1.76 per minute; surgery £3.54 per minute; embolic agent £86.31 per bottle (times four bottles); hospital stay £683 per day; MRI 
£243.16 per scan; US £29.09 per scan; and outpatient consultation £99 per visit.  The differences in costs between the surgical and UAE group were 
calculated using a bootstrap method, therefore the difference between the groups are not simple numerical ones.  One way sensitivity analysis were 
preformed on key unit-costs components by varying one measure at a time. 
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Discussion 
The initial 12 month results of the REST trial showed no difference in the quality of 
life gain between surgery and UAE.4 The 5 year results show this gain to be durable 
in both groups which achieved levels comparable with normative data from an age 
matched population. In addition, both treatments are associated with very high patient 
satisfaction scores of almost 90%. The symptom relief score, which was initially 
significantly better in the surgical arm at 12 months, continued to improve over the 
next 4 years in both arms of the study with ultimately no significant difference 
between groups. This may be related to the higher re-intervention rate (32%)  in the 
UAE arm and possibly a further reduction in uterine and fibroid volume over time. 
The re-intervention rate is significantly higher in the UAE group (32%) than the 
surgical group (4%) at 5 years. For the purpose of this trial re-intervention included 
all invasive treatments whether for complications, persistent or recurrent symptoms. 
Most of the re-intervention is for persistent or recurrent symptoms but we also saw 5 
patients who required either hysterectomy (n=3), endometrial ablation (n=1), or D&C 
(n=1) for complications related to UAE. There were also 5 patients in the UAE arm 
that either had a technical failure (n=3) or opted to have surgery in spite of being 
randomised to UAE (n=2). Interestingly the re-intervention rate  in the UAE arm 
increased from 13% at 12 months to 32% at 5 years. In contrast the intervention rate 
in the surgical arm remained at 4%. This is important new information when 
counselling patients. We found a similar trend regarding complications with the 
majority of the surgical arm complications occurring within the first 30 days whereas 
in the UAE arm most complications occurred beyond the traditional 30 day “surgical 
window”.   
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The EMMY trial (hysterectomy vs. UAE) has  recently reported a 28.4% 
hysterectomy rate for insufficient symptom control in the UAE arm.6 Our findings 
concerning the likelihood of re-intervention following UAE are similar to these. 
However, re-intervention following surgery was much lower in our study for reasons 
that are currently unclear. 
The HOPEFUL retrospective cohort study reported a further intervention rate of 23% 
at 4.6 years12 in the UAE group. The US fibroid registry (n=1916) followed up 1278 
(67%) and reported a further intervention rate of 14% at 3 years.13 In a non 
randomised study comparing UAE with myomectomy, the further intervention rate 
was 29% in the UAE arm and 3% after myomectomy.14 Not all re-intervention 
following UAE means a hysterectomy. UAE can be easily repeated and indeed 8 of 
the 29 re-interventions in REST were repeat UAE procedures. Despite the high 
further intervention rate in the REST trial, the average patient satisfaction, symptom 
relief and QoL scores remain high and similar in both groups at 5 year follow up. The 
cause of persistent and recurrent symptoms is likely to be multifactorial. Possible 
mechanisms include incomplete fibroid infarction, fibroid re-growth and non-fibroid 
related symptoms. The latter cannot be addressed by UAE whereas hysterectomy will 
effectively treat all causes of heavy menstrual bleeding and pressure symptoms 
resulting from the enlarged fibroid uterus. Katsumori has demonstrated a clear 
relationship between incomplete fibroid infarction and need for further intervention. 
He reported a cumulative re-intervention rate at 5 years, varying from 3% (with 
complete infarction) to 20% (with <90% infarction).15 The cause of incomplete 
infarction is poorly understood but factors such as the type of embolic agent used, 
embolic end point of the procedure and uterine collateral blood supply from ovarian 
vessels, are all likely factors.  
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Little is known about pregnancy outcomes after UAE and this trial was not set up or 
powered for this outcome. Of the 10 pregnancies in the UAE arm 4 (40%) resulted in 
early miscarriage with an additional ectopic pregnancy and one pre-term intra-uterine 
death. It is difficult to comment on these outcomes although recent publications 
suggest an increased incidence of spontaneous miscarriage, caesarean section and 
postpartum haemorrhage after UAE when compared with age-matched women with 
fibroids.16 Whilst one woman delivered pre-term, there were no cases of intra-uterine 
growth retardation or malpresentation, which is reassuring.  
There were no cases of premature ovarian failure (i.e. in women under 40 years of 
age) although gonadotrophins rose to post menopausal levels in a significant number 
of women over 45 years of age in both groups which is perhaps not surprising since 
FSH values increase with age. Further research is required in the group of women 
who wish to maintain their fertility as the possibility of embolic particles causing 
permanent loss of ovarian function and reserve cannot currently be excluded. A study 
will be required in women having the procedure prior to the age of 35 if this question 
is to be answered.. 
The initial cost benefit of UAE over surgery seen at 12 months was lost at 5 years due 
to the further intervention rate. The HOPEFUL study showed a similar outcome in 
cost effectiveness.17 
Limitations of this trial must be acknowledged. The original target number of 200 
patients was reduced to 157 owing to difficulty in recruitment. In addition, the 
number of women undergoing myomectomy was too small to draw any meaningful 
conclusions.  
In conclusion, the improvement in quality of life resulting from either surgery or UAE 
seen at 1 year was maintained and equal in both groups at 5 years with 91% follow 
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up. UAE is a safe and effective technique for women with symptomatic fibroids who 
wish to avoid conventional surgery (hysterectomy). Its safety profile (complication 
and adverse event rates) is similar to surgery, with most of the complications 
occurring within the first 12 months. Symptomatic relief and satisfaction with 
treatment are excellent in both groups.  
Almost a third of participants in the UAE arm required further invasive treatment. 
This resulted in the initial cost benefit at 1 year being lost at 5 years, with both 
treatments ultimately having a similar cost. The less invasive nature of UAE and its 
associated more rapid recovery needs to be balanced against the need for further 
intervention. The choice should lie with the informed patient. 
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